Pre-Conference Workshop Day New

Tuesday 26th March 2024

8:30am Workshop A

Advancing Drug Development for Brain Metastasis: From Target Identification to Clinical Trials

  • Adrienne Boire Neuro-Oncologist, Memorial Sloan Kettering Cancer Center


A deep dive into the critical aspects of drug development for brain metastasis, ultimately accelerating progress in this crucial area of oncology.

This workshop will gather experts to discuss:

  • Target identification and validation for brain metastasis
  • Leveraging molecular markers and pathways specific to brain metastasis and validating potential drug targets for their efficacy and specificity
  • Innovations in drug design and delivery for brain metastasis
  • Designing drug molecules to enable BBB penetration, exploring novel delivery systems and harnessing nanotechnology for targeted and susuatined drug release.
  • Optimizing preclinical models and trial design for brain metastasis research
  • Developing robust preclinical models, incorporating patient-derived xenografts and organoids for accurate drug screening and clinical trial endpoints relevant to brain metastasis treatment efficacy.

10:30 am Morning Break & Networking

11:00am Workshop B

Upgrading GBM Translational Models for Accelerated Therapeutic Advances

  • David nathanson Associate Professor - Molecular and Medical Pharmacology, UCLA School of Medicine
  • Nathalie Agar Associate Professor of Neurosurgery & of Radiology, Brigham & Women's Hospital at Harvard Medical School


Optimization of patient-derived models, innovations in translational platforms, and strategies to bridge the translational gap.

This workshop will gather experts to discuss:

  • Optimizing patient-derived models for personalized glioblastoma therapies
  • Implementing PDX and organoid models for more effective drug screening and enhancing treatment response prediction with in vitro and in vivo models
  • GBM translational models: Beyond the traditional
  • Exploring advanced 3D and ex vivo culture systems for glioblastoma research, harnessing organ-on-a-chip and microfluidic platforms for high-throughput screening and utilizing patient-derived organoids for modelling tumor heterogeneity and drug resistance
  • Review case studies highlighting successful translation of preclinical findings to clinical trials

1:00 pm Lunch

2pm Workshop C

Optimising Clinical Outcomes in GBM: Overcoming the Tumor Microenvironment & Optimising Biomarkers & Endpoints for Success


Discover expert-led insights to overcome GBM barriers like the immunosupressive tumor microenvironment and streamline the integration of novel therapies into clinical trials with an integration of the latest scientific insights into the TME and how we can use novel biomarkers & clinical endpoints to see successful translation of results into clinical trials.

This workshop will gather experts to discuss:

  • Understanding the multifaceted TME in GBM and translating expert TME insights into targeted therapeutic strategies
  • Leveraging advanced technologies to visualize and understand TME dynamics and personalizing treatment strategies based on this
  • Evaluating the synergistic potential of combining immunotherapies with other modalities to disrupt immunosuppressive signaling pathways in the TME and showcasing successful case studies of combinatorial strategies in overcoming the TME
  • Defining robust endpoints for the streamlined transition of new therapies into GBM clinical trials
  • Personalizing treatment strategies based on model responses and showcasing successful case studies of preclinical models influencing clinical trial outcomes
  • Leveraging cutting-edge biomarker technologies for patient stratification and enhancing early detection of treatment response and progression with dynamic biomarkers.